Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no ...

PH284 nasal spray increased hunger in cancer cachexia patients, showing a 71% improvement in subjective hunger scores compared to baseline. The phase 2A study demonstrated PH284's safety, with no ...

Two new composition of matter patents granted in the US and Europe Patents provide protection relating to lead compound S-pindolol benzoate ...

Evaluation of End-of-Life Quality Care Between American Indian and White North Carolina Decedents Diagnosed With Lung Cancer, 2003-2020 Cachexia is a systemic wasting syndrome prevalent in patients ...

In a recent study, researchers demonstrated that Z526, a novel dithiocarbamate-like compound, mitigates cancer-associated cachexia (CAC) both in vitro and in vivo.

Actimed Therapeutics’ anti-catabolic and pro-anabolic transforming agent, S-pindolol benzoate receives US & European patents: London, UK Friday, February 7, 2025, 16:00 Hrs [IST ...

Brain Tumor Organoids Accurately Model Patient Response to CAR T Cell Therapy ... target for the lethal wasting disease known as cancer cachexia. Their findings illustrate that even small groups ...

The impact of cancer cachexia on patients and the urgent need for new treatments has become increasingly apparent, and we continue to press ahead with our plans to bring our potential new therapy ...